Piscitelli Dominic sold $181K of ORIC
Piscitelli Dominic (Chief Financial Officer) sold 13,400 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.53 ($0.18M total) on 2026-09-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the CFO's ownership and may be interpreted as a lack of confidence, potentially prompting short‑term selling pressure.
Market read
Primary relevance is to ORIC shareholders; the filing provides fresh insider information that could affect short‑term price action.
What to watch
The CFO may be diversifying holdings; the transaction size is small relative to market cap.
Background
Form 4 filings disclose insider transactions; a CFO sale is noteworthy for investors monitoring insider activity.
Ticker impact
CFO sold 13,400 shares for $181,257 via a 10b5‑1 plan, reducing his stake to 69,828 shares.
likely slight downward pressure as the market prices in the sale
A CFO off‑loading $181k of stock is a material insider transaction for a small‑cap, often interpreted as a negative signal.
Market effects
Minimal impact on the broader biotech sector; only relevant to ORIC investors.
No regional effect beyond the US market.
Limited global relevance.
Counterpoint
The sale could be routine under a pre‑arranged 10b5‑1 plan and not reflect negative sentiment.
Key entities
- companyOric Pharmaceuticals, Inc.
US‑listed biotech company (NASDAQ: ORIC) whose CFO disclosed a stock sale.
- personDominic Piscitelli
Chief Financial Officer of Oric Pharmaceuticals who executed the sale.
